Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Wednesday, August 6, 2008

Paper: Transient trimethylaminuria in childhood, not because of poor enzyme function : 1998 Paper

This 1998 paper reports on two unrelated and otherwise healthy children with transient trimethylaminuria, a hitherto unknown abnormality, without N-oxidation deficiency. This demonstrates that a diagnosis of fish-odour syndrome should include the analysis of urinary excretion not only of trimethylamine but also of trimethylamine-N-oxide (TMAO).
Mayatepek E, Kohlmüller D
Children's Hospital, Heidelberg, Germany

Comment from the author who is a sufferer, not an expert:

There are 2 points of interest regarding this study. One is that it is now suggested that FMO1 is the most common form of the FMO enzyme in the human fetus. FMO3 then starts to express itself after birth, but can take quite a few years to fully develop. Around 9 or even teen years has been mentioned. FMO3 is the dominant FMO enzyme in humans after birth.

The other is that the paper suggests tma-n-oxide should be tested. Perhaps up until then, only tma levels were checked. Now 'primary TMAU' diagnosis seems to be based upon the levels of tma-n-oxide a person produces, since this is the correct finished metabolite. It may also explain why in the UK, they accept a diagnosis of 'Secondary TMAU', where the result is given because of too much TMA in the urine. In the case of the paper, today that would be regarded as Secondary TMAU cases (i.e. too much trimethylamine).


Post a Comment